Cargando…

Inflammation as a validated prognostic determinant in carcinoma of unknown primary site

BACKGROUND: Carcinoma of unknown primary (CUP) is a clinical presentation with a poor prognosis. Inflammation-based prognostic systems are stage-independent prognostic predictors in various malignancies. We aimed to assess the accuracy of the modified Glasgow Prognostic Score (mGPS), neutrophil/lymp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Z, Pinato, D J, Mauri, F A, Chen, K-W, Chang, P M-H, Sharma, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887290/
https://www.ncbi.nlm.nih.gov/pubmed/24169348
http://dx.doi.org/10.1038/bjc.2013.683
_version_ 1782478998403547136
author Mohamed, Z
Pinato, D J
Mauri, F A
Chen, K-W
Chang, P M-H
Sharma, R
author_facet Mohamed, Z
Pinato, D J
Mauri, F A
Chen, K-W
Chang, P M-H
Sharma, R
author_sort Mohamed, Z
collection PubMed
description BACKGROUND: Carcinoma of unknown primary (CUP) is a clinical presentation with a poor prognosis. Inflammation-based prognostic systems are stage-independent prognostic predictors in various malignancies. We aimed to assess the accuracy of the modified Glasgow Prognostic Score (mGPS), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) as objective prognostic models in CUP. METHODS: We derived inflammatory scores in 60 consecutive CUP referrals to the Imperial College oncology unit between 1996 and 2011. Patient demographics, treatment and staging data and full blood profiles were collected. An independent cohort of 179 patients presenting to the Taipei Veterens Hospital between 2000 and 2009 were used as a ‘validation' data set. Uni- and multivariate survival analysis was used to predict the overall survival (OS). RESULTS: Sixty patients were included: median age 61 (range: 33–86); 51% men; median OS 5.9 months (0.7–42.9); 88% with distant metastases. On univariate analysis NLR >5 (P=0.04) and mGPS (score 1–2) (P=0.03) correlated with OS. Multivariate analysis demonstrated significant hazard ratios for NLR; 2.02 (CI 1.0–4.1) (P=0.04) and mGPS; 1.52 (CI 1.0–2.3) (P=0.03). These findings were reinforced by analysis of the validation data. CONCLUSION: NLR and mGPS are independent, externally validated prognostic markers in CUP, with superior objectivity compared with performance status.
format Online
Article
Text
id pubmed-3887290
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38872902015-01-07 Inflammation as a validated prognostic determinant in carcinoma of unknown primary site Mohamed, Z Pinato, D J Mauri, F A Chen, K-W Chang, P M-H Sharma, R Br J Cancer Epidemiology BACKGROUND: Carcinoma of unknown primary (CUP) is a clinical presentation with a poor prognosis. Inflammation-based prognostic systems are stage-independent prognostic predictors in various malignancies. We aimed to assess the accuracy of the modified Glasgow Prognostic Score (mGPS), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) as objective prognostic models in CUP. METHODS: We derived inflammatory scores in 60 consecutive CUP referrals to the Imperial College oncology unit between 1996 and 2011. Patient demographics, treatment and staging data and full blood profiles were collected. An independent cohort of 179 patients presenting to the Taipei Veterens Hospital between 2000 and 2009 were used as a ‘validation' data set. Uni- and multivariate survival analysis was used to predict the overall survival (OS). RESULTS: Sixty patients were included: median age 61 (range: 33–86); 51% men; median OS 5.9 months (0.7–42.9); 88% with distant metastases. On univariate analysis NLR >5 (P=0.04) and mGPS (score 1–2) (P=0.03) correlated with OS. Multivariate analysis demonstrated significant hazard ratios for NLR; 2.02 (CI 1.0–4.1) (P=0.04) and mGPS; 1.52 (CI 1.0–2.3) (P=0.03). These findings were reinforced by analysis of the validation data. CONCLUSION: NLR and mGPS are independent, externally validated prognostic markers in CUP, with superior objectivity compared with performance status. Nature Publishing Group 2014-01-07 2013-10-29 /pmc/articles/PMC3887290/ /pubmed/24169348 http://dx.doi.org/10.1038/bjc.2013.683 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Epidemiology
Mohamed, Z
Pinato, D J
Mauri, F A
Chen, K-W
Chang, P M-H
Sharma, R
Inflammation as a validated prognostic determinant in carcinoma of unknown primary site
title Inflammation as a validated prognostic determinant in carcinoma of unknown primary site
title_full Inflammation as a validated prognostic determinant in carcinoma of unknown primary site
title_fullStr Inflammation as a validated prognostic determinant in carcinoma of unknown primary site
title_full_unstemmed Inflammation as a validated prognostic determinant in carcinoma of unknown primary site
title_short Inflammation as a validated prognostic determinant in carcinoma of unknown primary site
title_sort inflammation as a validated prognostic determinant in carcinoma of unknown primary site
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887290/
https://www.ncbi.nlm.nih.gov/pubmed/24169348
http://dx.doi.org/10.1038/bjc.2013.683
work_keys_str_mv AT mohamedz inflammationasavalidatedprognosticdeterminantincarcinomaofunknownprimarysite
AT pinatodj inflammationasavalidatedprognosticdeterminantincarcinomaofunknownprimarysite
AT maurifa inflammationasavalidatedprognosticdeterminantincarcinomaofunknownprimarysite
AT chenkw inflammationasavalidatedprognosticdeterminantincarcinomaofunknownprimarysite
AT changpmh inflammationasavalidatedprognosticdeterminantincarcinomaofunknownprimarysite
AT sharmar inflammationasavalidatedprognosticdeterminantincarcinomaofunknownprimarysite